Results 31 to 40 of about 19,626 (207)

Somatic cell reprogramming for Parkinson's disease treatment

open access: yesIbrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Limbic Structural Alterations and Structural Covariance Across Prodromal Phenotypes and Early Parkinson's Disease

open access: yesJournal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Non‐motor symptoms may precede motor diagnosis in Parkinson's disease (PD), but whether distinct prodromal phenotypes exhibit differential limbic structural alterations remains unclear. Purpose To investigate limbic structural alterations across prodromal PD phenotypes defined by rapid eye movement sleep behavior disorder (RBD) and ...
Yuanyuan Zhao   +6 more
wiley   +1 more source

Pediatric Epiglottopexy: A Scoping Review of Indications, Techniques, Outcomes, and Complications

open access: yesThe Laryngoscope, EarlyView.
This scoping review synthesizes the indications, techniques, outcomes, and complications of pediatric epiglottopexy across 24 studies comprising 371 patients from ten countries. Epiglottopexy, most often performed alongside supraglottoplasty, was associated with favorable respiratory and swallowing outcomes, though the evidence base consists ...
Karim Estephan, Mathieu Bergeron
wiley   +1 more source

Defining the Clinical Phenotypic Ground Truth: Expert Interrater Agreement in Hyperkinetic Movement Disorders

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Reliable clinical phenotyping is crucial for diagnosis, treatment, and research in hyperkinetic movement disorders, yet its interrater reliability remains uncertain. Objectives To quantify interrater agreement in clinical phenotyping of hyperkinetic movement disorders among experts in a large, phenotypically diverse cohort.
Madelein van der Stouwe   +43 more
wiley   +1 more source

Mobile Applications for Resting Tremor Assessment in Parkinson's Disease: A Systematic Review. [PDF]

open access: yesJ Clin Med, 2023
Moreta-de-Esteban P   +4 more
europepmc   +1 more source

JAK2 Variant and Parkinsonian Syndromes: Coincidence or Pathophysiological Link?

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background JAK2 variants are a hallmark of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia. These disorders are often associated with thrombotic and inflammatory complications. From a movement disorder perspective, chorea is a rare but well‐recognized neurological occurrence in this context ...
Elena Ardila Jurado   +5 more
wiley   +1 more source

Should Paratonia Be Considered a Movement Disorder? Implications for Clinical Management

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Paratonia is an involuntary and variable resistance to passive movement that emerges with cognitive decline in dementias of different etiologies, with prevalence approaching 90% to 100% in end‐stage disease. It is common in Parkinson disease and the atypical parkinsonisms.
Galit Kleiner   +2 more
wiley   +1 more source

A Multimodal Nomogram Predicting the Risk of Cognitive Impairment in Parkinson Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Cognitive impairment is the most consequential non‐motor complication of Parkinson's disease (PD), yet no validated tool integrates multimodal data to predict individualized risk trajectories. Objectives The aim is to develop and internally validate a time‐to‐event nomogram for predicting 5‐year risk of cognitive impairment in PD ...
Ahmed Negida
wiley   +1 more source

No Additional Benefit of 185 Hz Versus 130 Hz at Equivalent Energy in Deep Brain Stimulation for Tremor: A Randomized Prospective Clinical Trial

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Deep brain stimulation (DBS) of the ventral intermediate nucleus and posterior subthalamic area (VIM/PSA) in Essential Tremor (ET) and the subthalamic nucleus (STN) in Parkinson's disease (PD) are established treatments for tremor. To achieve maximum tremor control, increasing stimulation frequency beyond 130 Hz is part of clinical ...
Christina van der Linden   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy